Switch to
More onapp

Lupin Ltd

LUPIN
Health CarePharmaceuticals
MidcapWith a market cap of ₹29,842 cr, stock is ranked 161
Low RiskStock is 1.68x as volatile as Nifty
651.005.35 (-0.82%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
MidcapWith a market cap of ₹29,842 cr, stock is ranked 161
Low RiskStock is 1.68x as volatile as Nifty

Key MetricsEdit

PE RatioPE Ratio
-19.53
PB RatioPB Ratio
2.44
Dividend YieldDiv. Yield
0.61%
Sector PESector PE
34.21
Sector PBSector PB
4.18
Sector Div YldSctr Div Yld
0.94%

Forecast & RatingsDetailed Forecast 

26%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Pro Only

Earnings

Earnings Growth

Pro Only

Revenue

Rev. Growth

Pro Only

See Detailed Forecast

Company Profile

Lupin Limited is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) across the world.

Brands

Lupin

Pharmaceutical company

Investor PresentationView older 

Aug 4, 2022

PDF
View Older Presentations

Brands

Lupin

Pharmaceutical company

Financial TrendFinancial statements 

201920202021202215.1015.9915.3016.620.61-0.271.22-1.53
Revenue
Profit
Loss
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

ESOP/ESPS/SBEB Scheme 
Announced OnSep 26, 2022

Lupin Limited has informed the Exchange about allotment of 4271 shares under Lupin ESOP. | Download

Lupin Limited has informed the Exchange about allotment of 4271 shares under Lupin ESOP. | Download

Press Release 
Announced OnSep 22, 2022

Lupin Limited has informed the Exchange about press release dated 22-Sep-2022 titled Lupin Receives Approval from U.S. FDA for Diclofenac Sodium Topical Solution USP, 2% w/w. | Download

Lupin Limited has informed the Exchange about press release dated 22-Sep-2022 titled Lupin Receives Approval from U.S. FDA for Diclofenac Sodium Topical Solution USP, 2% w/w. | Download

Cash Dividend 
Ex. DateJul 14, 2022

Final • Div/Share: ₹ 4

See all events